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ABSTRACT 
 
Copy number alterations (CNAs) are thought to account for 85% of the variation in gene 
expression observed among breast tumours. The expression of cis-associated genes is impacted 
by CNAs occurring at proximal loci of these genes, whereas the expression of trans-associated 
genes is impacted by CNAs occurring at distal loci. While a majority of these CNA-driven 
genes responsible for breast tumourigenesis are cis-associated, trans-associated genes are 
thought to further abet the development of cancer and influence disease outcomes in patients. 
Here we present a network-based approach that integrates copy-number and expression profiles 
to identify putative cis- and trans-associated genes in breast cancer pathogenesis. We validate 
these cis- and trans-associated genes by employing them to subtype a large cohort of breast 
tumours obtained from the METABRIC consortium, and demonstrate that these genes 
accurately reconstruct the ten subtypes of breast cancer. We observe that individual breast 
cancer subtypes are driven by distinct sets of cis- and trans-associated genes. Among the cis-
associated genes, we recover several known drivers of breast cancer (e.g. CCND1, ERRB2, 
MDM2 and ZNF703) and some novel putative drivers (e.g. BRF2 and SF3B3). siRNA-
mediated knockdown of BRF2 across a panel of breast cancer cell lines showed significant 
reduction in cell viability for ER-/HER2+ (MDA-MB-453) cells, but not in normal (MCF10A) 
cells thereby indicating that BRF2 could be a viable therapeutic target for ER-/HER2+ cancers. 
Among the trans-associated genes, we identify modules of immune-response (CD2, CD19, 
CD38 and CD79B), mitotic/cell-cycle kinases (e.g. AURKB, MELK, PLK1 and TTK), and 
                                                          
 
DNA-damage response genes (e.g. RFC4 and FEN1). siRNA-mediated knockdown of RFC4 
significantly reduced cell proliferation in estrogen receptor-negative normal breast and cancer 
lines, thereby indicating that RFC4 is essential for cancer cell survival but could also be a useful 
biomarker for aggressive (ER-negative) breast tumours. Availability: 
http://bioinformatics.org.au/tools-data/ under NetStrat. 
1 INTRODUCTION  
With an estimated 1.38 million new cases diagnosed in a single year, breast cancer is the most 
common malignancy affecting women worldwide [1]. Sporadic breast cancer, which accounts 
for most (93-95%) breast cancer cases, is highly heterogeneous and is now understood to be a 
collection of diseases with distinct clinical and molecular phenotypes. Gene-expression 
profiling studies [2,3] have helped delineate this heterogeneity to a certain extent, by 
identifying at least four major molecular subtypes of sporadic breast cancer (PAM50 subtypes) 
– basal-like, HER2+, luminal-A and luminal-B. Each of these subtypes is associated with 
distinct clinical outcomes including patient survival, rates of disease progression and 
therapeutic response (reviewed in [4]). 
Although triggered by mutations in oncogenes such as PIK3CA and tumour-suppressor genes 
such as PTEN and TP53, breast tumours are largely characterized by amplifications, deletions 
or rearrangements of chromosomal regions (i.e. copy-number aberrations (CNAs)) rather than 
mutations (see [5]). These somatically acquired CNAs at gene loci account for roughly 85% of 
the variation in expression (covering ~40% of genes) seen in breast tumours [6]. When these 
CNAs affect driver genes (oncogenes and tumour suppressors) they further abet the 
development of cancer and influence disease outcomes in patients. For example, CNAs in 
FGFR1 and ZNF703 arising from aberrations in the chromosomal region 8p12 have been 
associated with worse prognosis in breast cancer patients [7,8]. Therefore, factoring CNA 
profiles of genes into the analysis of breast tumours is important to predict disease outcomes 
accurately and delineate the heterogeneity of breast cancer. 
Recent efforts into comprehensive profiling of breast tumours such as by The Cancer Genome 
Atlas (TCGA) [9] have enabled data integration across diverse datasets (e.g. gene expression 
and CNA). A landmark study by Curtis et al. [6] integrating copy number and gene expression 
in a discovery and validation set of 997 and 995 breast tumours, respectively, identified up to 
ten subtypes of breast cancer. That study analysed the impact of CNAs on expression variation 
by grouping genes as cis-or trans-associated to explain expression variation in these tumours. 
The expression of cis-associated genes is impacted by CNAs at proximal loci, whereas that of 
trans-associated genes is impacted by CNAs at other (distal) sites in the genome. By selecting 
the top 1000 cis-associated genes, constituting several cancer drivers, as features for input to 
an integrative clustering framework called iCluster [10], ten subgroups of breast cancer 
(integrative clusters 1-10) were identified that showed distinct disease-specific survival for 
patients. These ten subgroups were subsequently reproduced and validated in an independent 
dataset of expression profiles from about 7500 tumours [11].  
Several methodologies capable of integrating genome-wide CNA and expression profiles have 
since been developed (reviewed in [12]). For example, Adler et al. [13] proposed a stepwise 
approach, Stepwise Linkage Analysis of Microarray Signatures (SLAMS), in which expression 
signatures treated as ‘phenotype’ were associated with CNA signatures treated as ‘genotype’ 
to identify potential regulator genes. Ding et al. [14] present a visualization system called 
interactive Genomics Patient Stratification explorer (iGPSe) to visually explore disease 
subtypes in heterogeneous genomic data. Hofree et al. [15] present a framework using mutation 
profiles to subtype tumours; but being restricted to mutations, the method is less applicable to 
cancers of the breast and ovary that are largely associated with CNAs.  
To understand the role of CNAs in driving breast cancer tumorigenesis, it is important to 
consider both their cis- as well as trans-association in impacting the expression landscape of 
genes. Most identified CNA-drivers in cancers, for example ERRB2/HER2+, are cis-
associated; however, much less is known about trans-acting CNA events. Curtis et al. [6] note 
that poor prognosis observed in breast tumours in their integrative cluster 10 is due to 
overexpression of mitotic genes impacted in trans by specific deletion events at distal sites (on 
chromosome 5q). Consequently, expression changes in these trans-associated genes constitute 
the footprints of trans-acting CNAs that influence clinical outcomes.  
Here, we seek to identify cis- and trans-acting genes that drive breast tumours, using a network-
based approach. We analyse these genes in the context of the ten iCluster breast cancer subtypes 
as identified by Curtis et al. [6], and functionally validate selective genes whose overexpression 
correlates with poor prognosis in certain breast cancer subtypes. cis-Associated genes are 
typically identified by correlating CNA and expression profiles of genes; however, this 
typically leads to a long list of genes, many of which are co-expressed with one another. To 
prioritise our cis-associated set we employ a minimal vertex cover approach over a network 
(Figure 1a; discussed in detail in Methods). Specifically, we construct the network using 
correlation between CNA and expression profiles of genes as node weights and the co-
expression between genes as interaction weights, and compute a minimal weighted vertex 
cover to compose our cis-associated genes. To identify trans-associated genes, we employ a 
network propagation approach which iteratively computes the influence of CNAs on 
neighbouring genes in the network (Figure 1b; see Section 4.1 Methods). To validate our 
identified genes, we reconstruct the known ten clusters of breast cancer as identified by Curtis 
et al. [6]. We follow up on a cis-associated gene BRF2 and a trans-associated gene RFC4 using 
siRNA-mediated knockdown across a panel of breast cancer cell lines. BRF2 knockdown 
reduces cell proliferation by up to 75% in HER2+ cell lines, thereby strongly suggesting that 
BRF2 could be an oncogenic driver for these cells. On the other hand, trans-associated RFC4 
gene knockdown reduces cell proliferation (up to 60%) in ER-negative normal breast and 
cancer cell lines, thereby indicating that RFC4 could be an essential gene, but also a useful 
biomarker for aggressive (ER-negative) breast tumours. 
 
 
2 RESULTS 
2.1 Application to subtyping of breast tumours 
Selecting only genes common between the PPI and METABRIC discovery datasets produced 
a network Hw with 118646 interactions among 13038 genes, with 4150 interactions of absolute 
weights ≥  = 0.40. Identifying cis- and trans-associated genes using this network and setting 
the number of iterations I = 3 resulted in |Vcis | = 917 and |Vtrans | = 663 genes (overlap: |Vcis |  
|Vtrans | = 53), which were used to cluster the tumours.  
The cis-associated genes produced better clustering (assessed using Silhouette index; 
Supplementary files) than did the trans-associated genes, whereas combining the two sets 
performed better than either individually. Likewise using k = 10 produced better clustering, 
whereas k = 8 merged multiple clusters and k > 10 artificially broke apart clusters. Figures 2 
and S2 (clearer figures are available at the Supplemental website) shows disease-specific 
survival proportions for clusters produced using cis-, trans- and combined cis- and trans-
associated genes for k = {8, 9, 10}. The log-rank test p-values were highly significant (p < 
0.0001) in each of these cases, but the finer clusters produced at k = 10 (Figure S2i) still showed 
distinct survival patterns thereby representing different clinical subgroups. Therefore, we used 
k =10 in all our further analyses. 
Interestingly the trans-associated genes could separate out clusters with poor prognosis 
(clusters 5 and 7 in Figure 2) from the remaining clusters even though this set overlapped with 
the cis-associated genes only by about 8% (=53/663). Upon analyzing the contributions 
accumulated by these trans-associated genes in the poor-prognosis clusters, we found 
enrichment for cell-cycle and genome-stability functions (18.4% of genes, p = 2.1x10-35) with 
significantly higher contributions for poor-prognosis clusters compared to the remaining 
clusters (ANOVA test between the means p < 0.0001; Bartlett’s test: difference between stddev 
p < 0.0001) (Figure 3), indicating that these genes are associated in trans with the poor survival 
outcomes of these clusters. Curtis et al. note that their integrative cluster 10 is trans-influenced 
by several cell-cycle and genome-stability genes that are associated in trans with a deletion 
event at chromosome 5q. 
The ten clusters (Figure 2) produced from the cis- and trans-associated genes overlapped with 
the integrative clusters of Curtis et al. with an adjusted Rand index of 0.737 (ARI; a standard 
method for comparing two sets of clusters; [22]). We computed the overlap (Jaccard index) 
J(Oi, ICj) = |Oi  ICj|/|Oi  ICj| between each pair {Oi , ICj} of our cluster Oi and integrative 
cluster ICj. For J ≥ 0.50 and J ≥ 0.67, eight and six of the ten integrative clusters were recovered 
by our clusters, respectively. Clusters 4 and 8 which showed the worst prognosis at five years 
(Table 1) matched the integrative clusters 10 and 5, respectively. Clusters 1, 6 and 9 which 
showed a significant drop in survival by ten years (Table 1) covered the integrative clusters 1 
and 2. These findings agreed with the most-prominent grade, stage and number of positive 
lymph nodes at diagnosis for the ten clusters (Table 2; Figure S3): the aggressive clusters 4, 
6 and 8 represented grade 3 diseases with 2 to 4 positive lymph nodes on average.  
Regenerating these ten clusters using iCluster [10,11], but using our sets of cis- and trans-
associated genes, matched the Curtis et al. clusters with an ARI = 0.69. In particular, clusters 
7 and 8 were heterogeneous and produced similar (indistinguishable) survival patterns (Figure 
4a). But cluster 2, which matches our cluster 6, was more homogeneous and showed a 
significant drop in survival closer to 10 years. We also generated clusters from the METABRIC 
Validation dataset (Figure 4b), and these matched the Curtis et al. Validation clusters with an 
ARI = 0.49 (amounting to 8 and 6 integrative clusters recovered for J ≥ 0.50 and J ≥ 0.67, 
respectively).  
We next compared our clusters with the PAM50 subtypes which are annotated within the 
TCGA dataset. We obtained 1263 cis- and trans-associated genes which identified k = 5 
clusters (Figure 4c) with distinct overall survival patterns, and matching PAM50 subtypes with 
an ARI = 0.67. Cluster 1 was the most homogeneous and matched the basal-like subtype 
(~87%), whereas cluster 2 matched Her2+ (~76%), cluster 3 was composed of basal-like (23%) 
and luminal-B (~70%), cluster 4 was composed of luminal-B (~67%) and luminal-A (21%) 
and cluster 5 the luminal-A (~83%) subtype. 
Going back to Figure 2, clusters 4 and 8 matched the PAM50 subtypes basal-like and Her2+, 
whereas clusters 6 and 9 matched luminal-B. This again agrees with Tables 1 and 2: clusters 4 
and 8 represented grade 3 diseases and showed the steepest drop in survival cases within five 
years, which is characteristic of basal-like and Her2+ tumours [23]). Similarly, clusters 6 and 
9 also represented grade 3 disease but showed a significant drop in survival cases by ten years, 
which has been observed for luminal-B tumours (distant relapse) [23].  
 
2.2  In-depth analysis of cis- and trans-associated genes in the ten clusters 
Among the cis-associated genes we recovered were many known breast cancer drivers 
including CCND1, ERBB2, MYC, MDM2 and ZNF703 [6,8,24] which showed considerable 
gains (Figures S8, S9) with their over-expression significantly associated with poor survival. 
For example, ZNF703 is a regulator of cell adhesion, migration and proliferation. Over-
expression of ZNF703, attributed to amplification of the 8p12 region, has been frequently 
observed in estrogen-receptor positive (luminal) tumours with poor outcomes [8].  
Accordingly, we observed amplification and over-expression of ZNF703 in clusters 1 and 3 
(Figure S8) (matching integrative clusters 1 [luminal-B], 8 [luminal-A] and 9 [mixed]), which 
showed poor survival at ten years’ follow-up (Table 1). Over-expression of ZNF703 (≥75 
percentile) was noted in 94% of these tumours (Figure S4). 
The three splicing factors SF3B3, SF3B4 and SF3B5 showed contrasting patterns of CNAs 
(Figures S8, S9), with SF3B3 and SF3B5 showing losses whereas SF3B4 showing 
considerable gains across the tumour clusters. However, only the amplifications and 
corresponding over-expression of SF3B3, which was confined particularly to cluster 4 (basal-
like), associated with poor prognosis (Figures 5a). In particular, 40% of tumours showing very 
high expression (≥ 85 percentile) for SF3B3 and poor prognosis originated from cluster 4, 
which is predominantly basal-like (Figure 5b – in particular, compare the survival curves for 
very high (red) and low (green) expression levels; Figure S5). A recent study [25] has 
associated the overexpression of SF3B3 with poor prognosis in luminal (estrogen receptor-
positive) tumours, and our results complement this study by associating SF3B3 with also the 
poor prognosis of (a subset of) basal-like (estrogen receptor-negative) tumours. 
Another potentially interesting gene is BRF2, which is ranked second (behind only ERBB2) in 
our list of cis-associated genes in breast cancer. BRF2 is a subunit of the RNA polymerase II 
complex, which is required for transcription. Two earlier reports [37, 38] linked aberrant 
expression of BRF2 with deregulation of transcription in cancer cells, and therefore suggest 
BRF2 as a putative oncogene. In particular, a recent report [39] demonstrates that 
overexpression of BRF2 is required for the development of lung squamous cell carcinoma, and 
its activation is observed in >35% of lung cancers. We did not observe a significant association 
between the expression of BRF2 and survival in breast cancers. Nevertheless, Western blot 
analysis showed higher protein expression for BRF2 in several breast cancer cell lines, in 
particular HER2+ cell lines (Figure 6a). siRNA-mediated knockdown of BRF2 showed 
reduction in cell proliferation in some of these cell lines, in particular up to 75% reduction in 
the ER-/HER2+ cell line MDA-MB-453 (Figures 6b & 6c). But, the effect was not observed 
in normal MCF10A cells, suggesting that BRF2 might be a viable therapeutic target. Recent 
reports [40,41] support this view by suggesting that BRF2 could act as an ‘alternative driver’ 
for HER2+ breast cancers that do not express the HER2/ERBB2 gene. 
The analysis of trans-associated genes revealed enrichment for primarily two kinds of cellular 
processes (Figures S6 and S7): (i) immune-response functions including regulation of T-cell 
differentiation and activation (5.1%, p = 6.0x10-17), and antigen presentation (1.8%, p = 1.5x10-
8); and (ii) mitotic functions including M-phase (9.3%, p = 8.1x10-22), G2/M DNA-damage 
checkpoint (2.4%, p = 1.2x10-5), spindle checkpoint (0.8%, p = 1.5x10-3) and apoptosis (12.3%, 
p = 3.9x10-12). These genes showed distinct contribution values between the clusters (ANOVA: 
difference between means p < 0.0001; Bartlett’s test: difference between stddev p < 0.0001). 
In particular, the immune-response genes showed high contribution values for cluster 3 
(matching integrative cluster 4 (~40%)), suggesting a tumour subgroup trans-influenced by 
these genes.  
Among the mitotic genes were cell-cycle kinases AURKB, CDK1, CHEK1, MELK, PLK and 
TTK with the master regulator FOXM1 central to the mitotic network. These genes showed the 
highest contribution values for cluster 4 (matching integrative cluster 10 (~85%) and basal-like 
tumours), which displayed the worst prognosis at five years follow-up (Figure 2 and Table 1). 
Several of these are being explored as therapeutic targets in basal-like/triple-negative breast 
tumours (reviewed in [4,26]). In particular, knockdown of FOXM1 in specific cell lines 
including MDA-MB-231 reduces tumour-cell colony formation and increases sensitivity to the 
drug doxorubicin via reduction in the transcription of DNA-damage response (DDR) genes 
[27,28]. More recently, we have shown that inhibition of TTK significantly synergized with 
docetaxel in the treatment of aggressive triple negative breast cancer xenografts and exhibit as 
potential target in breast cancer [42].  Since most cell-cycle kinases have already been explored, 
we chose to follow up on RFC4, a replication factor gene and a downstream target of FOXM1. 
Overexpression of RFC4 was observed predominantly in clusters 4, 5 and 9 (basal-like and 
luminal-B) and correlated with poor survival in tumours (Figure 5a and c – in particular, 
compare the curves for very high (red) and low (green) expression levels). Western blot 
analysis showed higher expression for RFC4 in breast cancer cell lines compared to the near-
normal mammary epithelial cell line MCF10A (Figure 7a). Each of the two siRNAs against 
RFC4 reduced the expression of RFC4 by ≥ 50% compared to scrambled siRNA used as control 
(Figure 7b). Knockdown of RFC4 showed up to 70% reduction in cell proliferation in cancer 
cell lines with a higher trend visible for ER-negative (basal-like) cell lines, in particular BT549 
and MDA-MB-157 (Figure 7c). However, the knockdown suppressed proliferation also of 
MCF10A cells, up to 50%. These observations show that breast cancer cells exhibit higher 
expression of RFC4, whereas knockdown of RFC4 is lethal predominantly in ER-negative cell 
lines, which includes MCF10A. This also agrees with a recent large-scale cell-essentiality 
(siRNA knockdown) screen across 72 cancer cell lines [29] in which RFC4 is more essential 
in the ER-negative lines MDA-MD-231, MDA-MB-157 and BT549 compared to the ER-
positive lines MCF7 and T47D. RFC4 encodes the fourth-largest subunit of human replication 
factor C, a multimeric protein complex consisting of five subunits that functions as a clamp 
loader to load PCNA onto DNA during DNA synthesis [30, 31]. RFC4 also functions in DDR 
and checkpoint control through interaction with the DNA-damage checkpoint complex Rad17, 
9-1-1 [31,32]. Therefore, high expression of RFC4 could be reflective of high proliferation rate 
and higher number of proliferative cells in ER-negative cell lines. Furthermore, several recent 
reports have associated overexpression of RFC4 with poor prognosis in colorectal [33] and 
hepatocellular [34] cancers. Putting our findings together with these literature reports, we 
suggest that the expression of RFC4 is useful as a biomarker for aggressive breast tumours with 
its knockdown causing considerable reduction in proliferation of ER-negative cells. However, 
because RFC4 is an essential gene even for normal (MCF10A) cells, engaging it as a 
therapeutic target could be cytotoxic to some extent. 
We found 30 of the 444 cancer genes reported in the COSMIC census [43], and 6 of 37 genes 
affected by amplifications, deletions or rearrangements from Vogelstein’s list of cancer genes 
[44], to be among our cis-associated genes (Table S3). Most of these known cancer genes, e.g. 
CCND1 and MDM2, are affected by copy-number amplifications. We also found that some 
genes with roles in DDR, including FANCG, MLH1 and PALB2, were deleted. FANCG, a 
Fanconi anaemia group protein involved in the repair of DNA crosslinks, works closely with 
BRCA2. MLH1 is involved in the repair of DNA mismatches. PALB2 plays a crucial role in 
recruiting BRCA2 and RAD51 to sites of DNA breaks during homologous-recombination-
mediated DSB repair. These results suggest that apart from mutation and epigenetic silencing 
of these DDR genes, genomic deletions play an important role in the development of breast 
cancers. 
 
3 CONCLUSION 
Although breast cancers are triggered by somatic mutations in oncogenes such as PI3KCA and 
tumour-suppressor genes such as PTEN and TP53, their genomic landscape is dominated by 
chromosomal amplifications and deletions. These CNAs contribute to the development of 
breast cancer, and substantially influence survival and drug-response patterns in patients. Here, 
using a cohort of ~2000 breast tumours obtained from a recent comprehensive study [6], we 
develop a network-based approach to decipher this impact of CNAs on the expression 
landscape of genes by identifying cis- and trans-associated genes in breast cancers. To validate 
our sets of genes, we employ them to subtype the cohort into ten distinct clusters which closely 
match that from [6]. We note that individual clusters thus identified are driven by distinct sets 
of genes, for example by overexpression of ZNF703 in luminal clusters.  
 
Interestingly trans-associated genes, which are influenced by CNAs at distal foci and overlap 
very little (<8%) with cis-associated genes, show significant differences between their 
involvement in the clusters. This strongly suggests that CNAs in trans also play an important 
role in influencing differences between the clusters.  Our network approach identified 71 trans-
associated genes that were also highlighted in [6]. Among these, we found primarily two 
distinct functional modules – of mitotic/cell-cycle and immune-response genes (Figures S6 
and S7). Several of these cell-cycle/mitotic genes include kinases (e.g. AURKB, CDK1, 
MELK, PLK and TTK) which have been extensively explored as therapeutic targets (reviewed 
in [4,26]), genes involved in DNA replication (e.g. MCM2, MCM4, CDC7, CDC45 and RFC4), 
and also DDR genes (e.g. RFC4 and FEN1) with the master regulator FOXM1 at their core. 
 
Here, we demonstrate an effective pipeline from modeling to analysis and prediction, and 
experimental validation of our results. Our modeling framework presents an elegant way to 
decipher the functional influence patterns of CNAs, and is an effective computational 
alternative to exhaustive analysis of the genomic architecture and using an eQTL framework 
as adopted by Curtis et al. [6]. 
 
 
4 MATERIALS AND METHODS 
4.1 Identifying cis-associated genes 
We assemble a protein interaction (PPI) network H = (V, E), where V is the set of genes 
(proteins) and E is the set of interactions (unweighted and undirected) between these genes. 
Let T be the set of tumours, and G [n X m] and C [n X m] represent the gene-expression and 
CNA profiles spanning n genes from these |T|=m tumours, respectively. Using gene-
expression profiles G, each interaction (gx, gy)E is assigned a weight w(gx, gy) [-1,1] as the 
co-expression (as Pearson correlation) observed between gx and gy across the m tumours, 
resulting in a weighted network Hw. 
For each gene gx  V, we compute the node weight NV(gx) in Hw as  
NV(gx) = 1 - |(G[gx],C[gx])|,     (Eq. 1) 
where 0  |(G[gx],C[gx])|  1 is the correlation between CNA and expression profiles of gx 
across the m tumours. To identify cis-associated genes, we find the set of genes with minimal 
node weights which cover all the interactions in Hw, or in other words, we find the minimum 
weight vertex cover (MWVC) of Hw, formulated as: 
MWVC of Hw: Find a subset Vcis  V such that for every interaction (gx, gy)  E at least one of 
gx  or gy is in Vcis and the total weight ∑ 𝑁𝑉(𝑔𝑥)𝑔𝑥  𝑉𝑐𝑖𝑠  is minimized. 
In general, MWVC is NP-complete [16], but here we employ a heuristic approach to obtain a 
suboptimal solution, as follows. We pick an interaction (gx, gy) and select gx into Vcis if NV(gx) 
 NV(gy), marking all interactions incident on gx as covered. We repeat this until all interactions 
are covered, to identify the set of cis-associated genes Vcis. 
CNAs of cis-associated genes are strongly associated with expression variation, and for any 
cis-associated gene gx the correlation (G[gx],C[gx]) captures this association. Here, we use the 
top  genes in V with high correlation as our starting point. If any two of these genes gx and gy 
are also strongly co-expressed, as determined by |w(gx, gy)| ≥  (a  threshold), and if 
(G[gx],C[gx]) ≥ (G[gy],C[gy]) (modelled as NV(gx )  NV(gy )), then we select only gx  into 
Vcis. This reduces the redundancy of our selection (i.e. we select fewer genes) because we 
always pick gene gx with higher (G[gx],C[gx]) when gx and gy show similar expression profiles 
(Figure 1a) ( and  are empirically determined as explained later).  
 
4.2 Identifying trans-associated genes 
Unlike cis-associated genes, the trans-associated genes do not show a strong correlation 
between CNA and expression profiles, but instead their expression is influenced by CNAs of 
other (cis-associated) genes. We compute this influence on trans-associated genes using the 
interactions in Hw. However, since each tumour has a distinct CNA profile, the pattern of 
influence exerted by genes on each other varies considerably between tumours. Therefore, we 
compute the influence between genes for each tumour individually, and then select genes that 
accumulate a high overall influence across all tumours, as our set of trans-associated genes. 
For a tumour TsT, each gene gx in Hw is assigned an initial node weight NV(0)[Ts] (gx) = C[x,s] 
obtained from the CNA profiles C. Using the interactions in Hw, we propagate these node 
weights to neighbouring genes iteratively across the network (Figure 1b). In each iteration i  
1, the contribution CV(i)[Ts] (gx) that gx receives from its neighbours is computed as the 
interaction-weighted sum of node weights of neighbours, given by 
𝐶𝑉(𝑖)[𝑇𝑠](𝑔𝑥) =  
∑  (𝑤(𝑔𝑥,𝑔𝑧)).
 𝑁𝑉(𝑖−1)  [𝑇𝑠](𝑔𝑧𝑔𝑧 𝑁(𝑔𝑥) ).|𝑤(𝑔𝑥,𝑔𝑧)|
 𝑖
|𝑁(𝑔𝑥)|+ (𝑔𝑥)
,     (Eq. 2) 
where N(gx) is the set of neighbours of gx in H(G),  (w(gx, gz)) returns the sign of w(gx, gz), 
that is whether positive or negative, and (gx) is added to penalize genes with very few 
neighbours, given by: 
(𝑔𝑥) = max {0,
∑ |𝑁(𝑔𝑧)|𝑔𝑧𝑉
|𝑉|
−  |𝑁(𝑔𝑥)|}.     (Eq. 3)  
At each iteration, the above computation is performed for every gene gx in the network, and at 
the end of the iteration the node weights are synchronously updated,  NV(i)[Ts](gx) = NV
(i-
1)[Ts](gx) + CV
(i)[Ts](gx) for all genes. We perform i = I iterations, but dampen the contributions 
using an exponential decay of the interaction weights (since |w(gx, gz)|  1 in Equation 2). 
After executing the above procedure for every tumour Ts  T, we sum the contributions for 
each gene gx across all tumours,  
𝐶𝑉(𝐼)[𝑇](𝑔𝑥) =  ∑ |𝐶𝑉
(𝐼)[𝑇𝑠](𝑔𝑥)|𝑇𝑠∈𝑇, ,     (Eq. 4) 
and select genes with CV(I)[T] (gx) > 0, which is the union of all genes that accumulate non-
zero contributions, as our set of trans-associated genes Vtrans. 
Each gene gx receives contributions from its neighbours gz  N(gx) relative to the CNA of gz 
and the co-expression between gx and gz. If the CNA of gz affects the expression level of gz and 
if gz is co-expressed with gx, then we assume that the CNA of gz influences the expression of 
gx, thereby making gx a trans-associated gene. Equation 2 captures this influence as the co-
expression-weighted sum of CNAs from all neighbours gz for which |w(gx, gz)| ≥ . Through 
iterations, we account for neighbours up to I hops away (see Figure 1b). Genes that accumulate 
non-zero contributions (influence) are selected into Vtrans. 
 
4.3 Validation of cis- and trans-associated genes for breast cancer subtyping 
One way to validate our identified cis- and trans-associated genes and to understand their 
biological relevance is to use them for subtyping breast cancers. Here we use the expression 
profiles of the two sets of genes, Vcis and Vtrans as input features to a k-means clustering to 
identify tumour subgroups O = {O1,..., Ok}. We test k  [2, 15] and choose the k giving the 
best Silhouette index (a measure to assess clustering performance). We then validate these 
tumour subgroups using Kaplan-Meier survival plots.  
 
4.4 Datasets 
4.4.1 METABRIC dataset 
Clinical annotations, gene expression and CNA profiles for the discovery (997) and validation 
(995) set of tumours from the Curtis et al. [6] study were obtained by permission from the 
METABRIC consortium. Genes altered for copy number were located on the circular binary 
segmentation (CBS)-smoothed CNA segments from this dataset based on UCSC (h19) gene 
annotations [17] and processed using R packages [18], to generate a continuous log-ratio (CBS) 
smoothed CNA matrix for genes, with positive values meaning gains or amplifications and 
negative values meaning homozygous or heterozygous deletions. 
4.4.2 TCGA dataset 
Clinical annotations, gene expression and CNA profiles for 597 breast tumours were 
downloaded from the TCGA website (http://cancergenome.nih.gov). Based on molecular 
intrinsic (PAM50) subtyping these accounted for 81 basal-like, 58 HER2+, 132 luminal B, 235 
luminal A, 8 claudin-low tumours, with the remaining 83 unclassified. 
 
4.4.3 Protein interaction dataset 
Homo sapiens PPI data were downloaded from iRefIndex [19] which consolidates PPI data 
from multiple sources. Only those interactions annotated for direct physical or annotated 
reactions were selected. Removing self-, duplicate, false-positive interactions [20,21] resulted 
in a dense PPI network containing 176574 interactions among 19743 proteins (average node 
degree 17.81). 
 
4.5 Setting  and  
Parameter  identifies interactions in Hw that we wish to account for while determining the sets 
Vcis and Vtrans. We cover only those interactions with weights at least  for computing Vcis. 
Likewise, we use only these interactions to determine the neighbour contributions for 
computing Vtrans. In accordance with our assumption that the expression of a trans-associated 
gene gx is influenced by CNAs of its neighbours, reflected as co-expression with its neighbours, 
we wish to account for only those neighbours gy whose CNA patterns explain their co-
expression with gx. We found that using a cut-off  = 0.40 on gene co-expression accounted 
for 4150 interactions (gx, gy) of which ~83% (3443) showed CNAs in at least one of gx or gy, 
and their expression levels correlated with these CNAs with r = 0.69 (Figure S1). 
As noted in the Curtis et al. study, determining the top  cis-associated genes is somewhat 
arbitrary, so here we assessed the top P  [5, 25] percentile of genes with significant 
Benjamini-Hochberg p-values for CNA-to-expression correlation, and found P = 10, 
accounting for the top  = 1304 genes, was the lowest P sufficient to retain the 4150 
interactions. 
 
4.6 Experimental validation of RFC4 and BRF2 using siRNA-mediated knockdown 
Breast cancer cell lines were obtained from ATCC (Manassas, VA, USA) and cultured 
routinely per ATCC instructions. All cell lines were regularly tested for mycoplasma and 
authenticated using Short Tandem Repeat (STR) profiling by the QIMR scientific services core 
facility. For siRNA experiments, 10 nM siRNAs were reverse transfected using Lipofectamine 
RNAiMAX (Life Technologies, Carlsbad, CA).  
 
We obtained the following siRNAs Shanghai Gene Pharma (Shanghai): 
siRFC4_S1: 5-GACGUACCAUGGAGAAGGAGUCGAA-3;  
siRFC4S2: 5-GCAGCAGUUAUCUCAGAAUUGUUAA-3;  
siBRF2_S1: 5-GCAGGGAUGACUAUAGGUAGGAGAG-3; 
siBRF2_S2: 5-GCAGUUGCCACCAACAUUUGAGGAT-3; 
siBRF3_S3: 5-CUGCCUCACGGUUGCUGUUGCAGAC-3 and  
siSC: 5-UUCUCCGAACGUGUCACGUTT-3. 
Six days after siRNA knockdown, cell viability was determined using the CellTiter 96® 
AQueous One Solution per the manufacturer’s instructions (Promega, Fitchburg WI, USA). 
For immunoblotting, standard protocols were used and membranes were probed with 
antibodies against RFC4 (anti-RFC4 [N1C3]), BRF2 (anti-BRF2 [N1C1]) (GeneTex CA, 
USA) and γ-tubulin (Sigma-Aldrich, Sydney), and developed using Chemiluminescence 
Reagent Plus (Millipore, Billerica, MA, USA). 
All data and associated analysis are available at: http://bioinformatics.org.au/tools-data/ under 
NetStrat. 
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Figure 1: Identifying cis- and trans-associated genes. (a) cis-associated genes are identified 
by correlating expression and CNA profiles. We choose the top- genes that show high 
correlation, and identify a vertex cover subset (MWVC) that is representative of these top 
genes; and (b) trans-associated genes are identified by propagating node weights across 
neighbouring genes in the network. Gene gx receives contributions from the 2-hop neighbour 
gq via the 1-hop neighbour gp when the iteration reaches i = 2, because gp would have received 
contributions from gq in iteration i = 1. 
  
  
Figure 2: Kaplan-Meier plots of disease-specific survival (truncated at 15 years) for clusters 
identified using cis- (917), trans- (663) and combined cis- and trans-associated (1527) genes 
(arranged horizontally) for k = 10 clusters from the Discovery dataset (998 tumours). Log-rank 
test p-value in each of the cases was significant (p < 0.0001). A clearer figure is available from 
Supplementary website. Please also see Figure S2. 
  
 Figure 3: Contribution values accumulated by trans-associated genes involved in cell cycle 
and genome stability (genes highlighted also in Curtis et al. [6]). The clusters show significant 
differences between their contribution-means (ANOVA test: p-value < 0.0001). Clusters 5, 7 
and to some extent 4 and 10 show higher contributions for these genes and the clusters show 
poorer prognosis, whereas cluster 3 with the lowest contribution shows better prognosis (Figure 
2).  
  
 Figure 4: Validation on the METABRIC Validation and TCGA cohorts [6]. (a) Clusters 
generated using iCluster [10]. (b) Disease-specific survival plots for k = 10 generated using the 
1527 cis- and trans-associated genes on the Validation dataset (995 tumours). (c) Overall 
survival plots for k = 5 generated using 1263 cis- and trans-associated genes on the TCGA 
dataset (597 tumours). Log-rank test p-value was not significant (p = 0.148), but this could be 
because of very few deceased cases (about 135) in the TCGA cohort.  
 Figure 5: (a) Fraction (%) of tumours (out of 997) with amplifications for RFC4 and SF3B3 
in the ten clusters (ERBB2 is a known oncogene); match cluster numbers with Figure 2. 
Amplifications for SF3B3 and RFC4 were most common for cluster 4. (b) & (c) Survival 
proportions for disease-specific survival in patients stratified by percentiles of expression levels 
of (b) SF3B3 and (c) RFC4. Over-expression of these genes correlates with poor survival; 
~40% of tumours showing very high expression (≥ 85 percentile) come from cluster 4, which 
represents predominantly basal-like tumours. Compare red (very high) and green (low 
expression) curves for better indication of the differences in survival. 
  
 Figure 6: Western blot and siRNA-mediated knockdown of BRF2 in breast cancer cell lines: 
(a) basal expression level of BRF2 across a panel of cell lines; (b) knockdown efficiency using 
siRNAs S1 and S2 for BRF2 (SCR: scrambled siRNA used as control); and (c) cell viability 
upon BRF2 knockdown (****p<0.0001; ***p<0.001; **p<0.01). 
  
 Figure 7: Western blot and siRNA-mediated knockdown of RFC4 in ER-negative and ER-
positive breast cancer cell lines: (a) basal expression level of RFC4 across a panel of cell lines; 
(b) knockdown efficiency using siRNAs S1 and S2 for RFC4 (SCR: scrambled siRNA used as 
control); and (c) cell viability upon RFC4 knockdown (****p<0.0001; ***p<0.001; 
**p<0.01). 
 
  
Tables 
 
 
Table 1: Number of patients at risk and total deaths for the ten clusters of Figure 2. S(X) is the 
% of patients surviving at X months. 
 
 
 
Table 2: Most-prominent grade, stage and number of positive lymph nodes at diagnosis for 
patients in the ten clusters of Figure 2 (also see Figure S3). 
Cluster 1 2 3 4 5 6 7 8 9 10 
#Risk 
101 114 92 81 150 89 154 102 47 66 
#Deaths 33 15 23 31 41 24 20 39 20 14 
#S(60) 91.3 90.7 79.7 65.8 89.2 80.7 95.7 63.2 77.5 83.5 
#S(120) 64.4 81.9 70.1 59.4 74.3 59.9 85.3 56.8 57.8 79.1 
Cluster 1 2 3 4 5 6 7 8 9 10 
Grade 
2 2 3 3 2 3 2 3 3 2 
Stage 0 2 3 3 2 2 2 2 1 2 
#Lymph 1 2 3 2 2 4 2 4 2 2 
